Historical ew News Stories
Edwards Lifesciences Q1 Beat, Guidance Lift EW
Edwards Lifesciences reported a stronger-than-expected Q1 with $1.65B revenue, raised full-year guidance, and completed a $500M accelerated buyback—boosting sentiment even as valuation remains rich and institutional trimming surfaces.
Edwards Lifesciences: CMS NCA & EU Probe Update
Key regulatory moves — EU antitrust probe closed and CMS launched its NCA for asymptomatic TAVR — plus insider buys and FDA RWE shifts that materially affect Edwards Lifesciences (EW).
Edwards' Lifesciences: Recall, R&D & Insider Buys.
Edwards Lifesciences faced a voluntary recall of its Sapphire TAVR valve this week, introducing short-term sales pressure amid a company reorganization. At the same time, the firm's proxy confirms continued heavy R&D investment and strong regulatory progress, while recent insider purchases signal management confidence. Investors should weigh near-term operational risks against long-term innovation momentum.
Edwards Lifesciences Gets Goldman Buy, $89 Target
Goldman Sachs reiterated a Buy rating and set an $89 target on Edwards Lifesciences (EW), citing TAVR strength and TMTT growth opportunities. Technical analysis this week also showed bullish momentum with short-term support near $83–$84 and resistance around $87–$89 — offering defined risk-reward for investors.
Edwards Lifesciences: Q4 Beat, EU Win; Shares Surge
Edwards Lifesciences (EW) saw a notable stock uptick after a stronger-than-expected Q4 revenue print, lifted guidance for 2026, and resolved an EU antitrust probe by removing its anti-copycat policy. Key drivers: robust TAVR performance, rapid TMTT growth, FDA approval of SAPIEN M3, and disciplined capital returns.
Edwards Lifesciences Gains After Q4 Results Rally!
Edwards Lifesciences (EW) climbed after Q4 results showed revenue slightly above estimates despite an EPS miss. Elevated trading volume, a premium valuation, and upbeat guidance underpin analyst optimism and investor interest in this S&P 500 medtech name.
Edwards Lifesciences: Q4 Beat Sparks Volatility
Edwards Lifesciences reported mixed Q4 results with strong revenue growth driven by TAVR and TMTT products, an EPS miss, and a bullish 2026 outlook. The stock showed sharp post-earnings swings as investors weighed near-term investment plans against long-term growth guidance. Key drivers to monitor include TAVR reimbursement progress, execution on TMTT expansion, and trading volume signaling institutional positioning.
Edwards Lifesciences: Volume Spike Drives Pullback.
Edwards Lifesciences (EW) experienced elevated trading volume and several days of share-price decline in early February 2026, underperforming peers despite solid fundamentals and recent product approvals. Key drivers include heightened investor rebalancing, the commercial ramp of SAPIEN M3, and upcoming clinical data and guidance milestones.